The requested article has expired, and is no longer available. Any related articles, and user comments are shown below.
© Thomson Reuters 2021.Novavax bosses cash out for $46 mil with COVID-19 vaccine trials still under way
By Jessica DiNapoli NEW YORK©2024 GPlusMedia Inc.
3 Comments
Login to comment
Sal Affist
They know if their vaccine is unsuccessful, or if the competitors' vaccines are so successful that no one buys Novavax, their company value will go back to $250M again. So get it while the getting is good.
Also, cashing out their gains before the incoming administration and Democrat congress vacate the favorable tax rates from the Tax Cuts and Jobs Act.
Wick's pencil
Cashing out on a 34 year old company which has yet to bring a vaccine to market. Not very encouraging!